JP2024540922A5 - - Google Patents
Info
- Publication number
- JP2024540922A5 JP2024540922A5 JP2024523525A JP2024523525A JP2024540922A5 JP 2024540922 A5 JP2024540922 A5 JP 2024540922A5 JP 2024523525 A JP2024523525 A JP 2024523525A JP 2024523525 A JP2024523525 A JP 2024523525A JP 2024540922 A5 JP2024540922 A5 JP 2024540922A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal according
- approximately
- solution
- powder
- ray diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163257073P | 2021-10-18 | 2021-10-18 | |
| US63/257,073 | 2021-10-18 | ||
| PCT/EP2022/078989 WO2023066941A1 (en) | 2021-10-18 | 2022-10-18 | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540922A JP2024540922A (ja) | 2024-11-06 |
| JP2024540922A5 true JP2024540922A5 (enExample) | 2025-10-27 |
Family
ID=84359608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523525A Pending JP2024540922A (ja) | 2021-10-18 | 2022-10-18 | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250066382A1 (enExample) |
| EP (1) | EP4419530A1 (enExample) |
| JP (1) | JP2024540922A (enExample) |
| CN (1) | CN118451082A (enExample) |
| WO (1) | WO2023066941A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018060501A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating uterine fibroids and endometriosis |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| WO2021069700A1 (en) | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101153042A (zh) | 2003-01-29 | 2008-04-02 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
| SMT202200255T1 (it) | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| TWI744224B (zh) | 2015-02-26 | 2021-11-01 | 日商武田藥品工業股份有限公司 | 固形製劑 |
| SI3518932T1 (sl) | 2016-09-30 | 2025-03-31 | Takeda Pharmaceutical Company Limited | Zdravljenje raka prostate |
| WO2018060501A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating uterine fibroids and endometriosis |
| WO2019178304A1 (en) * | 2018-03-14 | 2019-09-19 | Teva Pharmaceuticals International Gmbh | Solid state forms of relugolix |
| JP2022551316A (ja) | 2019-10-10 | 2022-12-08 | ミオバント サイエンシズ ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形 |
| WO2021069700A1 (en) | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
-
2022
- 2022-10-18 WO PCT/EP2022/078989 patent/WO2023066941A1/en not_active Ceased
- 2022-10-18 JP JP2024523525A patent/JP2024540922A/ja active Pending
- 2022-10-18 CN CN202280069988.XA patent/CN118451082A/zh active Pending
- 2022-10-18 EP EP22805826.9A patent/EP4419530A1/en active Pending
-
2024
- 2024-04-16 US US18/636,642 patent/US20250066382A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551525A5 (enExample) | ||
| JP2022551316A5 (enExample) | ||
| KR100207360B1 (ko) | 이미다조[1,5,-a]퀸옥살린 | |
| JP4193949B2 (ja) | Ｉ型グリシン輸送阻害剤としての二環式［３．１．０］ヘテロアリールアミド | |
| ES2604542T3 (es) | Arilamidas con sustitución tetrazol | |
| US5629331A (en) | Process for the preparation of a tetrazole derivative in two crystalline forms and novel the crystalline forms thereof | |
| JP4740115B2 (ja) | 置換ピラゾール | |
| JP6240164B2 (ja) | ピロール誘導体の結晶及びその製造方法 | |
| US20090149505A1 (en) | Metabotropic Glutamate Receptor-Potentiating Isoindolones | |
| JP2024505063A5 (enExample) | ||
| JP2008514642A5 (enExample) | ||
| TW200838511A (en) | Novel pharmaceutical compounds | |
| TW200521115A (en) | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | |
| EP2118067A1 (en) | Nicotinic acetylcholine receptor modulators | |
| JPH06508370A (ja) | アンジオテンシン２拮抗活性を有する４−（１ｈ−ピロール−１−イル）イミダゾール | |
| JPH054391B2 (enExample) | ||
| CN112409293B (zh) | 苯并噻嗪酮化合物及其制备方法与作为抗结核药物的应用 | |
| JP2013542255A (ja) | ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素 | |
| CN101115755A (zh) | 作为mglur2拮抗剂的吡唑并-嘧啶衍生物 | |
| AU2004228121B2 (en) | 1,3,4-substituted pyrazoles for use as 5-HT receptor antagonists in the treatment of psychoses and neurological disorders | |
| JP2022533340A5 (enExample) | ||
| JP2024514090A5 (enExample) | ||
| JP2022535870A (ja) | Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途 | |
| WO2024193530A1 (zh) | 萘胺类线粒体自噬诱导剂的固体形式、其制备方法、药物组合物和用途 | |
| AU2004228119B2 (en) | Pyrazole compounds |